Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 clinical trial for ASLAN003 in inflammatory bowel disease

Trial Profile

Phase 2 clinical trial for ASLAN003 in inflammatory bowel disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Farudodstat (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Therapeutic Use

Most Recent Events

  • 06 Dec 2021 According to an ASLAN Pharmaceuticals media release, the company will be collaborating with IQVIA Biotech for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials.
  • 26 Oct 2021 According to an ASLAN Pharmaceuticals media release, the company expects to initiate this trial in he first half of 2022.
  • 13 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top